Loading
institutionsInstitution
National University Hospital / National University Cancer Institute, Singapore
Singapore's university hospital cancer institute, paired with the Cancer Science Institute of Singapore and known for gastric cancer, haematology and drug development research.
Also called: NCISNUHNUS Yong Loo Lin School of MedicineCancer Science Institute of Singapore
Overview
The National University Cancer Institute, Singapore (NCIS) is the cancer arm of the National University Hospital and the National University Health System, working alongside the Cancer Science Institute of Singapore, a research centre of excellence founded in 2008 that has produced leading work on gastric cancer genomics (Patrick Tan), leukaemia biology, RNA editing and cancer epigenetics. NCIS runs Singapore's largest haematology and stem cell transplant programme, a phase 1 unit with a long record of first-in-human trials, and genomic and pharmacogenomic research on Asian populations (Goh Boon Cher, Soo Ross). The Yong Loo Lin School of Medicine's Saw Swee Hock School of Public Health contributes to the Singapore Chinese Health Study and cancer epidemiology. Patients have access to CAR-T, transplant, robotic surgery and trials across all major tumour types.
Location
Singapore, SG
Type
hospital · National University of Singapore
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#275 · 24 points (0 Newsweek + 0 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to National University Hospital, including child institutions. 293 works · 4,443 citations · 69% open access · 8% clinical trials · 11% reviews.
Oncology works per year
632022
602023
672024
722025
312026
Most works
- Shing Fung Lee17 works
- Ker‐Kan Tan17 works
- Raghav Sundar16 works
- Mikael Hartman15 works
- Jingmei Li14 works
- Peh Joo Ho13 works
- Wei Peng Yong10 works
- Ross A. Soo10 works
- Jerrald Lau10 works
- Katsuro Ichimasa10 works
Most cited
- Cancer Science Institute of Singapore
- Gastric cancer genomics
- Haematology and transplant
- Phase 1 drug development
- Cancer epidemiology
Chee Cheng Ean
Executive Director
Medical oncologyGastrointestinal cancersCancer service leadership
Medical oncologist who leads Singapore's National University Cancer Institute (NCIS), the country's public cancer centre for adults and children.
Goh Boon Cher
Deputy Director (Research)
Medical oncologyEarly-phase drug developmentHead and neck cancer
Senior medical oncologist and translational researcher who leads research at NCIS, with a long record in experimental therapeutics and head and neck cancer.
Jimmy So
Head, Division of Surgical Oncology; Associate Director (Tumour Groups)
Surgical oncologyGastric cancerUpper gastrointestinal surgery
Gastric cancer surgeon who heads surgical oncology at NCIS and coordinates its multidisciplinary tumour groups.
Similar pages
- InstitutionMax Healthcare (Max Institute of Cancer Care)
Shares Robotic & minimally invasive surgery, CAR-T cell therapy, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.
- InstitutionRuijin Hospital, Shanghai Jiao Tong University
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), CAR-T cell therapy, Acute myeloid leukaemia, Gastric & gastro-oesophageal junction cancer.
- InstitutionSiriraj Hospital, Mahidol University
Shares Robotic & minimally invasive surgery, CAR-T cell therapy, Acute myeloid leukaemia, HR-positive / HER2-negative breast cancer.
- InstitutionChinese PLA General Hospital
Shares Robotic & minimally invasive surgery, CAR-T cell therapy, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
- InstitutionSeoul St. Mary's Hospital
Shares Robotic & minimally invasive surgery, CAR-T cell therapy, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
- InstitutionTohoku University Hospital
Shares Whole-exome & whole-genome sequencing, Gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
- InstitutionRajiv Gandhi Cancer Institute and Research Centre
Shares Robotic & minimally invasive surgery, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
- CompanyFoghorn Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.